Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms
Recruitment status was: Not yet recruiting
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat the cancer.
PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with peripheral T-cell lymphoma or natural killer cell neoplasms.
Genetic: DNA analysis
Genetic: cytogenetic analysis
Genetic: gene mapping
Genetic: mutation analysis
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis
|Official Title:||The Molecular Mechanisms of Transformation in Peripheral T-cell and NK Lymphomas|
- New somatically mutated genes in T-cell and NK lymphoma samples
- Prognostic significance of mutations in genes and pathways with cell proliferation, survival, and response to epigenetic therapy
|Study Start Date:||August 2011|
|Estimated Primary Completion Date:||September 2011 (Final data collection date for primary outcome measure)|
- To identify mutations in oncogenes and tumor suppressors of peripheral T-cell lymphoma or natural killer (NK) cell neoplasm.
- To delineate the mechanisms that mediate oncogenic effects and their clinical prognostic significance in these diseases.
- To perform a comprehensive mutation analysis via whole exome resequencing in a panel of peripheral T-cell or NK lymphomas.
OUTLINE: Fixed paraffin-embedded tumor tissue samples are analyzed for mutations by the Illumina HiSeq platform. Sequencing reads are performed by GAPipeline version 1.5.1 and mapping on the human genome performed using the MAQ software version 0.7.1. Genes harboring validated somatic mutations are then amplified by PCR and analyzed by Sanger resequencing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01390597
|Principal Investigator:||Adolfo A. Ferrando, MD, PhD||Herbert Irving Comprehensive Cancer Center|